Saying she is “disappointed, saddened and deeply concerned” by the price hike of the EpiPen, actor Sarah Jessica Parker has cut ties with the company that makes the emergency allergy treatment.
Parker, whose 13-year-old son James has severe peanut and hazelnut allergies, was part of a short campaign with pharmaceutical giant Mylan N.V., maker of the EpiPen. She was never a spokeswoman.
The company is facing heated criticism about the list price of an EpiPen twin-pack climbing to $608 over the past nine years.
Parker took to Instagram on Thursday to distance herself from the company and urged it to “take swift action to lower the cost to be more affordable for whom it is a life-saving necessity.”
It’s been an honor working with the #AnaphylaxisForReel initiative as a #spokesperson for Mylan this past month and encouraging people to share their stories about managing potentially life-threatening (severe) allergies. As the mother of a child with severe allergies, raising awareness and starting a discussion about the risks of anaphylaxis is so important to me. Join the cause by sharing your experiences at Anaphylaxis101.com. X, Sj
A representative for the actress confirmed the statement was accurate.
Also, the people are loving her for it:
Sarah Jessica Parker gives me so much hope— soleil (@foxymoronn) August 26, 2016
Follow @htshowbiz for more